Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Liabilities and Shareholders Equity (2020 - 2025)

Maravai Lifesciences Holdings has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $770.6 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $770.6 million for Q4 2025, down 23.57% from a year ago — trailing twelve months through Dec 2025 was $3.5 billion (down 32.82% YoY), and the annual figure for FY2025 was $770.6 million, down 23.57%.
  • Liabilities and Shareholders Equity for Q4 2025 was $770.6 million at Maravai Lifesciences Holdings, down from $849.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for MRVI hit a ceiling of $2.3 billion in Q1 2023 and a floor of $770.6 million in Q4 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $1.5 billion (2021), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 51.15% in 2022 and later crashed 43.63% in 2024.
  • Maravai Lifesciences Holdings' Liabilities and Shareholders Equity stood at $1.9 billion in 2021, then increased by 18.98% to $2.3 billion in 2022, then plummeted by 34.83% to $1.5 billion in 2023, then crashed by 32.22% to $1.0 billion in 2024, then decreased by 23.57% to $770.6 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $770.6 million (Q4 2025), $849.2 million (Q3 2025), and $897.0 million (Q2 2025) per Business Quant data.